As of Nov 18, 2026, 2 of 2 active firms rate CTXR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CTXR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.38 – $-0.38 · 1 analysts
Next period, 1 analysts expect Citius Pharmaceuticals Inc to earn $-0.38 a share (range $-0.38 – $-0.38), versus — a year earlier. Full-year consensus is $-2.03, growing to $-1.44 the year after.
REVENUE · NEXT QUARTER
$4.4M
Range $4.4M – $4.4M · 1 analysts · +12% YoY
Revenue is expected to reach $4.4M (range $4.4M – $4.4M), +11.6% year-over-year., rising to $20.5M next year.
Top analysts covering Citius Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTXR.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$4.00+662.5% to target
Overall win rate
38%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$6.00+1043.7% to target
Overall win rate
22%
+ Follow
#3
Michael Okunewitch
Maxim Group
Neutral
No targeton CTXR
Coverage
—
+ Follow
CTXR stock forecast FAQ
What is CTXR's average 12-month price target?+
The 2 active firms with a live target average $5.00 for Citius Pharmaceuticals Inc over the next 12 months, ranging from a $6.00 high to a $4.00 low, as of Nov 18, 2026.
Is CTXR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 18, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CTXR?+
The Street-high target is $6.00 (D. Boral Capital), and the Street-low is $4.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $5.00.
How many active Wall Street firms cover CTXR?+
2 active firms have a recognized rating on Citius Pharmaceuticals Inc as of Nov 18, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CTXR?+
Among analysts who currently cover CTXR, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #321). Their current call is Buy with a $4.00 target.
What is Citius Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.38 – $-0.38) across 1 analysts. Full-year EPS is projected at $-2.03, rising to $-1.44 the following year.
How much revenue is Citius Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $4.4M (range $4.4M – $4.4M). Full-year revenue is projected at —, growing to $20.5M next year.
Have analysts been upgrading or downgrading CTXR lately?+
As of Nov 18, 2026, 2 of 2 active firms rate CTXR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTXR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.